11.02.22
Hello all MARCo friends!
We've been getting some really great questions from our campaign backers, customers, and potential partners about MARCo and our company, and as such we've started to notice some trends in questions that keep coming up. That's why we've decided to start a Q&A series to answer some of the hottest questions around everyone's favorite robot companion!
For the first in the series, we wanted to peer into the future and take a glimpse at where we believe we can drive this company in the future.
Today's question - What conditions/demographics will future MARCo's likely target?
We currently believe the first condition that we will move towards an FDA approval for is major depression, and we currently intend to follow up on that with approval for assisting individuals struggling with generalized anxiety disorder (GAD). The reasons we are choosing to focus on these conditions first are a) the scale of the problem is enormous (major depression is the #1 cause of disability in the world), and b) these conditions are frequently comorbid, so addressing one without the other is not ideal.
However, we believe that will not mean that MARCo will be boxed in to only those conditions. What we see as the advantage of the MARCo platform is that the same hardware, and much of the same software, can be reused across demographics and conditions with only modifications made specific to one target. We believe this will allow us to quickly pivot our products into new markets once we have optimized it once with a combination of real world and clinical data.
The next target condition/demographic will be primarily driven by where we see the strongest interest and parallelism to our current technology. That remains to be seen; however, there are some strong indicators of future possibilities.
For instance, at the AACAP conference we attended two weeks ago, we had multiple conversations with hospital staff interested in learning if MARCo could provide companionship support to pediatric medical patients hospitalized for surgery. In early October, we engaged with members of the National Institute of Aging (NIA) to discuss future research for MARCo for quality of life care for elderly Alzheimer's and dementia patients. Additionally, we have had MARCo's brought to classrooms for work with students struggling with developmental and behavioral disabilities.
We see these three areas - patient comfort, elderly care, and behavioral support - as strong potential future areas where MARCo can excel. We intend to focus on youth depression and anxiety in the early stages, but we believe these positive indicators bode well for future directions of MARCo once we have cleared regulatory steps for the first conditions.
If you have a question you would like to see answered, please comment down below with your question and we'll get back to you ASAP!
And to all our backers, I want to say again, thank you for joining our mission. If you want to see your impact and investment go even further, please make sure to share our company and campaign with anyone and everyone you may know who may be interested. And even if you are just following for now, a share can go a long way, so please do consider sharing and spreading the word.
Thank you all and stay tuned for the next latest and greatest update in MARCo's journey!
Sincerely,
Jacob Boyle
CEO - MARCo Health Inc.
Website: https://www.marcohealthtech.com
Facebook: https://www.facebook.com/marcohealthtech
Instagram: @marcotherobot
TikTok: @marcotherobot
LinkedIn: https://www.linkedin.com/company/marco-technologies-llc/